Hereditary Angioedema: Clinical Trials

35 trials for Hereditary Angioedema, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

27 completed, 3 active not recruiting, 2 enrolling by invitation, 1 recruiting. 35 Phase 3, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 335Completed 27, Active not recruiting 3, Enrolling by invitation 2, Recruiting 1, Terminated 1, Withdrawn 1
Phase 26Completed 4, Enrolling by invitation 1, Withdrawn 1

Follow Hereditary Angioedema: new trials by email Literature Review of Hereditary Angioedema trials Research Report on Hereditary Angioedema

Trials (filtered) newest first · largest first

All 35 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
ADX-324, Placebo - Hereditary Angioedema, HAE
Phase 3RecruitingADARx Pharmaceuticals, Inc.902025-08-282026-09-10
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
NTLA-2002, Normal Saline IV Administration - Hereditary Angioedema
Phase 3Active not recruitingIntellia Therapeutics802025-01-152026-10-08
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
KVD900 150 mg, KVD900 300 mg, KVD900 600 mg - Hereditary Angioedema
Phase 3CompletedKalVista Pharmaceuticals, Ltd.362024-08-012026-08-05
Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Deucrictibant, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I
Phase 3CompletedPharvaris Netherlands B.V.1342024-02-262025-11-21
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
deucrictibant - Hereditary Angioedema, Hereditary Angioedema Type I
Phase 2 / Phase 3Enrolling by invitationPharvaris Netherlands B.V.1502022-12-282026-07-21
Berotralstat Treatment in Children With Hereditary Angioedema
Berotralstat - Hereditary Angioedema, Pediatric
Phase 3Active not recruitingBioCryst Pharmaceuticals292022-10-252026-02-25
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
KVD900 600 mg, KVD900 300 mg - Hereditary Angioedema
Phase 3CompletedKalVista Pharmaceuticals, Ltd.1452022-10-242026-06-05
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
KVD900 600 mg, Drug: KVD900 300 mg - Hereditary Angioedema
Phase 3CompletedKalVista Pharmaceuticals, Ltd.112022-10-242026-06-08
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
Donidalorsen - Hereditary Angioedema
Phase 3Active not recruitingIonis Pharmaceuticals, Inc.1542022-07-132025-12-12
A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Placebo, KVD900 600 mg, KVD900 300 mg - Hereditary Angioedema
Phase 3CompletedKalVista Pharmaceuticals, Ltd.1362022-02-222025-05-02
OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)
Donidalorsen, Placebo - Hereditary Angioedema
Phase 3CompletedIonis Pharmaceuticals, Inc.912021-12-032025-03-06
Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema
GNR-038, 50 МЕ/ kg, GNR-038, 100 МЕ/ kg, Berinert®, 20 МЕ/ kg - Hereditary Angioedema
Phase 2 / Phase 3WithdrawnAO GENERIUM2021-12-012022-02-04
Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies
berotralstat - Hereditary Angioedema, HAE
Phase 3Enrolling by invitationBioCryst Pharmaceuticals1392021-07-232025-12-23
Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks
CSL312 - Hereditary Angioedema
Phase 3CompletedCSL Behring1712021-03-292026-06-02
Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema
TAK-743 300 mg - Hereditary Angioedema
Phase 3CompletedTakeda122021-02-102023-06-26
CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks
CSL312, Placebo - Hereditary Angioedema
Phase 3CompletedCSL Behring642021-01-272023-06-29
A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema
TAK-667 - Hereditary Angioedema
Phase 3CompletedTakeda22021-01-152022-03-29
A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children
Lanadelumab - Hereditary Angioedema
Phase 3CompletedShire212019-08-192022-05-26
A Long Term Safety Study of BCX7353 in Hereditary Angioedema
BCX7353 - Hereditary Angioedema, HAE
Phase 2 / Phase 3CompletedBioCryst Pharmaceuticals3872018-02-162023-06-18
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
BCX7353 capsules, Placebo oral capsule - Hereditary Angioedema, HAE
Phase 3CompletedBioCryst Pharmaceuticals1212018-02-062023-06-26

Showing 20 of 35. Sign in to see all of them.

Narrower conditions

Angioedemas, Hereditary (35)  ·  Angioedema (4)  ·  Genetic Diseases, Inborn (2)  ·  Hereditary Angioedema Type III (2)  ·  Hereditary Angioedema Types I and II (2)  ·  Hypersensitivity (1)  ·  Immune System Diseases (1)

Broader conditions

Cardiovascular Diseases (35)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (35)  ·  Hereditary Complement Deficiency Diseases (35)  ·  Hypersensitivity, Immediate (35)  ·  Immunologic Deficiency Syndromes (35)  ·  Primary Immunodeficiency Diseases (35)  ·  Skin Diseases (35)  ·  Skin Diseases, Vascular (35)  ·  Skin and Connective Tissue Diseases (35)  ·  Urticaria (35)  ·  Vascular Diseases (35)  ·  Hypersensitivity (34)  ·  Immune System Diseases (34)  ·  Genetic Diseases, Inborn (33)  ·  Angioedema (31)

Interventions

Complement C1 Inhibitor Protein (10)  ·  Sodium Chloride (6)  ·  berotralstat (4)  ·  icatibant (4)  ·  sebetralstat (4)  ·  avoralstat (2)  ·  conestat alfa (2)  ·  donidalorsen (2)  ·  lanadelumab (2)  ·  IONIS-PKK-LRx (1)  ·  RNA, Small Interfering (1)  ·  Tranexamic Acid (1)

Sponsors

Shire (8)  ·  BioCryst Pharmaceuticals (6)  ·  CSL Behring (4)  ·  KalVista Pharmaceuticals, Ltd. (4)  ·  Pharming Technologies B.V. (3)  ·  Ionis Pharmaceuticals, Inc. (2)  ·  Pharvaris Netherlands B.V. (2)  ·  Takeda (2)  ·  ADARx Pharmaceuticals, Inc. (1)  ·  AO GENERIUM (1)  ·  Intellia Therapeutics (1)  ·  Johann Wolfgang Goethe University Hospital (1)

Countries

United States (24)  ·  Canada (21)  ·  Germany (20)  ·  France (17)  ·  Israel (16)  ·  Spain (16)  ·  United Kingdom (16)  ·  Hungary (14)  ·  Italy (14)  ·  Netherlands (12)  ·  Poland (12)  ·  Australia (11)  ·  Bulgaria (10)  ·  Japan (10)  ·  Romania (10)

Top investigators

Anurag Relan, MD (1)  ·  Bruce Zuraw, MD (1)  ·  Henriette Farkas, MD (1)  ·  Henriette Farkas, MD, PhD, DSc (1)  ·  Jan Nuijens, MD, PhD (1)  ·  Jolanta Bernatoniene, MD (1)  ·  Lauge Farnaes, MD (1)  ·  Marc Riedl, MD MS (1)  ·  Oksana A. Markova, MD (1)  ·  Vesna Grivcheva-Panoska, MD, PhD (1)  ·  Wolfhart Kreuz, PD Phd (1)

Results publications

PMID 36326435, PMID 20818886, PMID 23312695, PMID 42159953, PMID 20920772, PMID 22856635, PMID 23484892, PMID 23987198, PMID 28284978, PMID 36408587, PMID 40380356, PMID 40886933, PMID 42268494, PMID 17073887, PMID 19767078, PMID 20674826, PMID 20818888, PMID 21195947, PMID 21884533, PMID 22123383, PMID 22192966, PMID 22856636, PMID 22909164, PMID 23167682, PMID 23535096, PMID 24111645, PMID 24266596, PMID 24438203, PMID 25198193, PMID 25295804, PMID 26556097, PMID 33098856, PMID 33866032, PMID 34161665, PMID 35820771, PMID 36774155, PMID 36868261, PMID 37730089, PMID 38006972, PMID 38020288, PMID 38819395, PMID 40380363, PMID 40490218, PMID 40673861, PMID 40716738, PMID 41208217, PMID 41252457, PMID 41767175, PMID 42294842, PMID 42318595

NIH funding

2004 (2), 2008 (1), 2009 (1), 2018 (1), 2023 (1)